IL286197A - Stable topical compositions of phenoldopam - Google Patents

Stable topical compositions of phenoldopam

Info

Publication number
IL286197A
IL286197A IL286197A IL28619721A IL286197A IL 286197 A IL286197 A IL 286197A IL 286197 A IL286197 A IL 286197A IL 28619721 A IL28619721 A IL 28619721A IL 286197 A IL286197 A IL 286197A
Authority
IL
Israel
Prior art keywords
fenoldopam
topical compositions
stable topical
stable
compositions
Prior art date
Application number
IL286197A
Other languages
English (en)
Hebrew (he)
Inventor
Helena Shifrin
Alexandra Shraifel
Vered Rosenberger
Ron Schlinger
Tzviel Sheskin
Avi Avramoff
Original Assignee
Taro Pharma Ind
Helena Shifrin
Alexandra Shraifel
Vered Rosenberger
Ron Schlinger
Tzviel Sheskin
Avi Avramoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind, Helena Shifrin, Alexandra Shraifel, Vered Rosenberger, Ron Schlinger, Tzviel Sheskin, Avi Avramoff filed Critical Taro Pharma Ind
Publication of IL286197A publication Critical patent/IL286197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL286197A 2019-03-08 2021-09-06 Stable topical compositions of phenoldopam IL286197A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815893P 2019-03-08 2019-03-08
PCT/IB2020/051967 WO2020183322A1 (en) 2019-03-08 2020-03-06 Stable topical compositions of fenoldopam

Publications (1)

Publication Number Publication Date
IL286197A true IL286197A (en) 2021-10-31

Family

ID=69846519

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286197A IL286197A (en) 2019-03-08 2021-09-06 Stable topical compositions of phenoldopam

Country Status (11)

Country Link
US (2) US11446237B2 (https=)
EP (2) EP3908255B1 (https=)
JP (2) JP7124234B2 (https=)
CN (2) CN116966129A (https=)
AU (2) AU2020236525B2 (https=)
BR (1) BR112021017140A2 (https=)
CA (1) CA3131049A1 (https=)
ES (1) ES2941241T3 (https=)
IL (1) IL286197A (https=)
NZ (1) NZ781774A (https=)
WO (1) WO2020183322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023257375A1 (en) 2022-04-21 2024-11-07 Glaukos Corporation Ophthalmic topical cream compositions

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
ATE210975T1 (de) 1994-06-23 2002-01-15 Procter & Gamble Topisch anzuwendende zubereitungen enthaltend n- acetyl-l-cystein
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
AU3869399A (en) 1998-04-27 1999-11-16 Elan Pharmaceuticals, Inc. Transdermal administration of fenoldopam
JPH11335236A (ja) 1998-05-22 1999-12-07 Shiseido Co Ltd 皮膚外用剤
EP1100476B1 (en) * 1998-07-24 2004-06-16 ALZA Corporation Formulations for the transdermal administration of fenoldopam
US6699497B1 (en) 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
US7358236B1 (en) 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
WO2005079851A2 (en) 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
WO2005108387A2 (en) 2004-05-03 2005-11-17 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
CN101151028A (zh) * 2005-03-03 2008-03-26 Isw集团公司 局部用凝胶组合物
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
JP2009502206A (ja) 2005-08-03 2009-01-29 ミニュー・セラピューティクス・リミテッド 腫瘍壊死因子アルファ（ＴＮＦ−α）合成および分泌を調節するための、Ｔ細胞におけるＫｖ１．１電位依存性カリウムチャンネルのモデュレーション、およびＴＮＦ−αの有害な高または低レベルを介しての人の疾患または傷害の治療
WO2009052491A2 (en) 2007-10-18 2009-04-23 Geraghty, Erin Fenoldopam formulations and prodrug derivatives
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009076553A1 (en) 2007-12-11 2009-06-18 Monroe Stephen H Composition of aqueous buffer solution for the treatment of cellular environment and ion channels and methods for using same
CA2732439A1 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
JP2011144143A (ja) 2010-01-15 2011-07-28 Shiseido Co Ltd 皮膚外用剤
RU2571277C2 (ru) 2010-10-21 2015-12-20 Галдерма С.А. Композиции геля с бримонидином и способы применения
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
FR2991177B1 (fr) 2012-06-01 2014-12-19 Galderma Res & Dev Compositions topiques, contenant un retinoide, de type emulsion huile dans eau sans emulsionnant
AU2014227996B2 (en) * 2013-03-15 2018-08-23 Vapogenix, Inc. Novel analgesic compositions
JP6893075B2 (ja) 2014-08-04 2021-06-23 日東電工株式会社 液性免疫誘導促進用組成物及びワクチン医薬組成物
UA121985C2 (uk) * 2015-01-23 2020-08-25 Др. Редді'З Лабораторіз Лімітед Нефарбуюча гелева композиція для місцевого застосування, яка містить німесулід
EP3506906A4 (en) * 2016-08-31 2020-08-12 Taro Pharmaceutical Industries Ltd. TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
MX2020004187A (es) * 2017-10-24 2020-09-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica de adapaleno y minociclina.

Also Published As

Publication number Publication date
EP4218719A2 (en) 2023-08-02
EP3908255B1 (en) 2023-01-11
WO2020183322A1 (en) 2020-09-17
ES2941241T3 (es) 2023-05-19
JP2022160648A (ja) 2022-10-19
CN113543773B (zh) 2023-07-14
EP3908255A1 (en) 2021-11-17
BR112021017140A2 (pt) 2021-11-09
US20230059107A1 (en) 2023-02-23
AU2022202941A1 (en) 2022-05-26
EP4218719A3 (en) 2023-09-20
US11446237B2 (en) 2022-09-20
CN116966129A (zh) 2023-10-31
JP2022515569A (ja) 2022-02-18
AU2020236525B2 (en) 2022-02-03
CA3131049A1 (en) 2020-09-17
NZ781774A (en) 2023-03-31
CN113543773A (zh) 2021-10-22
AU2020236525A1 (en) 2021-11-04
JP7124234B2 (ja) 2022-08-23
US20220040089A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
IL276443A (en) Compounds for topical administration for the treatment of pain
ES3063371T3 (en) Topical ophthalmological compositions
IL274099A (en) Stable formulations of PEG-modified carfilzomib formulations
GB201913701D0 (en) Composition of matter
IL304159A (en) A preparation containing bl-8040
IL277213A (en) Topical preparation
GB202013432D0 (en) Compositions
IL290324A (en) Preparations containing tropintide
EP3927868C0 (en) USE OF SULFIDIC COMPOSITIONS
GB202015836D0 (en) Compositions
IL272944A (en) local preparations
IL286197A (en) Stable topical compositions of phenoldopam
GB202105461D0 (en) Compositions
GB202102704D0 (en) Compositions
GB202002052D0 (en) Compositions
IL308895A (en) Topical formulation of dimethylcurcumin
IL284072A (en) local preparations
IL273213A (en) Topical preparations of chloroprocaine
GB202108009D0 (en) Stable composition
GB202117631D0 (en) Topical compositions
GB201918039D0 (en) Topical composition
GB202015404D0 (en) Topical composition
GB202012836D0 (en) Topical composition
HK40065908A (en) Compositions of trofinetide
GB202114311D0 (en) New compositions